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Background: Some patients suffer from persistent and severely disabling Obsessive-
Compulsive Disorder (OCD) symptoms that cannot be alleviated by conventional
treatments or neuroablative interventions targeting cortico-striatal loop circuits.
Currently, it is unclear how to manage the clinical symptoms of these unique patients.
We reasoned that deep brain stimulation (DBS) of the habenula (HB) could be a valuable
subsequent treatment option for these otherwise medically intractable cases of severe
OCD. The HB is an epithalamic structure critically involved in the encoding and responding
to aversive stimulus events, cognitive and brain processes known to be impaired in many
patients with OCD. Similarly, HB DBS can alleviate depression and anxiety, which often
co-occur with OCD. Here, we explore the clinical beneﬁts and risks of HB DBS treatment
in a patient with severe and refractory OCD.
Case Presentation: A 30-year-old male patient presented with persistent and severely
disabling OCD symptoms that were refractory to previous psychological and
pharmacological treatments as well as to neuroablative surgical interventions involving
both capsulotomy and cingulotomy. After HB DBS, however, the severity of the patient's
OCD symptoms was markedly reduced at 1-month follow-up, which was sustained until
the ﬁnal (at 12-month) follow-up. The patient also reported enduring improvements in
depression, anxiety, and health-related quality of life after several months of HB
DBS treatment.
Conclusions: This case report provides the ﬁrst clinical evidence suggesting that HB
DBS could serve as a safe and effective alternative neurosurgical intervention for severe
and refractory OCD. The present ﬁndings are promising and warrant further research into
the role of the HB in pathophysiology and treatment of OCD.
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OCD is a psychiatric disorder with a lifetime prevalence of 1–3%.
Pharmacotherapy and psychological intervention, particularly
cognitive behavioral therapy (CBT), are the ﬁrst-line therapies
for OCD, achieving an overall response rate of 40–60%. Among
the non-responders, about 10% is characterized by persistent and
severe clinical symptoms, which profoundly impair the patient's
functioning and quality of life. As a result, neurosurgical
interventions, particular ablative surgery and deep brain
stimulation (DSB), have been employed in an effort to manage
the severely disabling and treatment-refractory OCD symptoms
in this subset of patients. Although the pathophysiology of OCD
remains incompletely understood, preclinical and clinical studies
have implicated the involvement of abnormal functioning in
medial and orbital frontal-basal ganglia–thalamic circuits. In line
with this hypothesis, stereotactic neurosurgical lesions made in
the anterior limb of the internal capsule, the anterior cingulate,
or the subcaudate region, lesions that all affect the key circuits
implicated in OCD pathophysiology, can improve severe OCD
symptoms in patients who are refractory to conventional
treatments. However, ablative neurosurgical interventions are
not reversible and have traditionally been considered as a last
resort intervention for severe and refractory OCD. Moreover,
stereotactic ablative neurosurgical interventions are not effective
for all patients, yielding a response rate of 50–60% (1).
Correspondingly, it is currently unclear how to manage
patients with severely disabling OCD symptoms who have also
failed to respond to stereotactic ablative surgery (2).
We reasoned that DBS of the habenula (HB) could offer a
promising subsequent treatment option for these otherwise
medically intractable cases of severe OCD. The HB is an
epithalamic structure that serves as an important link between
forebrain and midbrain regions. This structure has recently
received much clinical interest because it modulates both
dopaminergic and serotonergic neurotransmission (3). The
lateral HB is believed to play a crucial role in negative reward
processing, particularly the anticipation of aversive sensory
stimuli (via input from basal ganglia) and the behavioral
responses to stress, pain, fear-provoking or other aversive
stimulus events (via input from the limbic system), ultimately
functioning to suppress motor activities that lead to an aversive
outcome (4). Because OCD is associated with core deﬁcits in
stimulus avoidance learning and behavioral control (5), we
hypothesized that DBS of the HB could be a novel and
effective subsequent treatment option for those patients who
have failed to respond to stereotactic ablative surgery. Moreover,
several studies have reported that HB DBS treatment can
alleviate affective disturbances in patients with refractory mood
disorders (6, 7). Therefore, HB DBS could serve to improve not
only the symptoms of OCD but also associated cognitive deﬁcits,
depression, anxiety, and quality of life. Here, we describe an adult
male patient who had failed to respond to ablative surgery but
subsequently showed widespread clinical improvements over
one year of HB DBS treatment.Frontiers in Psychiatry | www.frontiersin.org 2Case Presentation
At the time of HBDBS surgery, the patient was 30 years of age and
had suffered from severe OCD (according to DSM-IV criteria)
since the age of 15 (Table 1). His primary symptoms consisted of
both obsessions and compulsions, including intrusive negative
thoughts, excessive cleaning behaviors, and “just right” feelings.
He had tried but failed to respond to evidence-based psychological
treatments, including cognitive behavioral therapy. Similarly, his
OCD symptoms had failed to respond to multiple trials of
pharmacotherapy of adequate duration and dose, including
augmenting medications (Table 1). In 2012, the patient
underwent bilateral anterior capsulotomy, but this neurosurgical
intervention had limited therapeutic effects; the patient selection
criteria used for this surgical intervention has been described
elsewhere (8). In 2014, the patients received bilateral
cingulotomy, which was also mostly ineffective. Subsequently,
the patient was offered HB DBS after he had requested us to
consider a potential further treatment for his severely disabling
OCD symptoms. The patient was then enrolled in a study on HB
DBS treatment for refractory OCD. This study was approved by
the Ruijin Hospital Ethics Committee of Shanghai JiaoTong
University School of Medicine. Written informed consent was
obtained for study participation and the publication of this case
report. Bilateral HB DBS electrodes (L301, PINS, Beijing) were
implanted under general anesthesia. The surgical procedure used
to target the HB and implant the electrodes has been described in
another study (6).
On the same day of the HB DBS surgery, the location of the
electrodes implanted in the HB was conﬁrmed and the HB DBS
treatment initiated. Clinical outcome assessments were
repeatedly performed over the study follow-period of 12
months by an experienced rater who was not blinded to the
patient's condition and HB DBS treatment. The patient's dosage
of medications before surgery was kept ﬁxed during the study
follow-up. After DBS parameter optimization (6), the ﬁnal DBS
parameters used were: left: C+2-, 1.6 V, 60 ms, 60 Hz; right: C+2-,
1.35 V, 60 ms, 60 Hz. The coordinates of active contacts were X =
89.7, Y = 99.7, Z = 96.7; X = 100, Y = 99.9, Z = 95.7 (Figure 1).
We utilized a relatively low voltage and pulse width to lower the
risk of adverse side effects in this patient, such as headache andTABLE 1 | Patient's demographic and clinical characteristics.
Gender Male
Age 30
Marriage Married
Occupation Unemployed
Illness Duration 15 years
Hospitalization times 6
Drug Trials Fluvoxamine, Fluoxetine, Citalopram,
Clomipramine, Olanzapine, Magnesium Valproate,
Trihexyphenidyl
Drug Usage
Pre-operation
Fluvoxamine (100mg/d);
Benzhexol (2mg/d);
Olanzapine(7.5mg/d);
Magnesium Valproate (0.25g/d)February 2020 | Volume 11 | Article 29
Zhang et al. Habenular DBS for OCDdizziness. The side effects of different stimulation threshold
values are listed in Table 2.
After the onset of HB DBS, the severity of the patient's OCD
symptoms was markedly reduced at 1-month follow-up (Table
3). The improvements in both his obsessions and compulsions
were maintained over the course of the entire follow-up period.
At 12-month follow-up, the patient's overall level of OCD
symptoms, as measured by using the total score on the Yale-
Brown Obsessive-Compulsive Scale (YBOCS-II) (10), was
reduced by about 35% as compared to his total score obtained
at baseline (Table 3). After HB DBS onset, the patient also
reported improvements in depression, anxiety, and health-
related quality of life at 3-month follow-up, which were
sustained until 12-month follow-up (Table 3). The patient's
sleep quality was not affected consistently by the HB
DBS treatment.Frontiers in Psychiatry | www.frontiersin.org 3Discussion and Conclusion
We utilized HB DBS in an effort to manage chronic and severely
disabling OCD symptoms in a unique patient who had failed to
respond not only to conventional treatments but also to
stereotactic ablative neurosurgery (capsulotomy and
cingulotomy). After HB DBS onset, the patient showed aTABLE 2 | Adverse side effects of different stimulation threshold values.
Right Habenula Left Habenula
Contact 1- 2- 3- 4- 1- 2- 3- 4-
Voltage/
V
2 1 1 1 1 1 3 3
Side
Effect
Dizzy Dizzy
Numb
Nausea
Dizzy Dizzy
Nausea
Dizzy
Flustered
Dizzy Dizzy
Flustered
Dizzy
Nausea
NumbCase+, 60 ms, 60 Hz.FIGURE 1 | (A) DBS electrodes placed in the habenula region (purple) using the Thomas Atlas (Saranathan, 2019) as visualized by reconstructing preoperative T1,
T2, and postoperative CT images. (B) Illustration that the volumes of activated tissues (red) induced by the DBS electrodes overlap with the patient's habenula
nuclei. (C) A view of the habenula (purple), volume of activated tissues (red), and the adjacent thalamic regions (blue) using the Thomas Atlas (9).TABLE 3 | Clinical assessment before and after deep brain stimulation surgery.
Rating Scale Baseline 1 m 1.5 m 3 m 4.5m 6 m 7.5 m 12 m
YBOCSII 31 21 25 19 21 22 25 20
Obsession 19 11 15 10 12 13 15 12
Compulsion 12 10 10 9 9 9 10 8
HDRS 11 6 8 5 9 7
HARS 13 11 8 7 8 9
PSQI 5 3 7 5 6
EQ-5D-5L
Mobility 2 1 1 1 1
Self-care 1 1 1 1 1
Usual activity 1 1 1 1 1
Pain/Discomfort 2 1 1 1 1
Anxiety/Depression 2 2 2 1 2
Health today 60 80 90 95 80February 2020 | Volume 11 | ArtiYBOCSII, Yale-Brown Obsessive-Compulsive Scale, Second Edition;
HDRS, 17-item Hamilton Depression Rating Scale;
HARS, Hamilton Anxiety Rating Scale;
PSQI, Pittsburgh sleep quality index;
EQ-5D-5L, EuroQol-5 Dimension-5 Level;
m, Month(s).cle 29
Zhang et al. Habenular DBS for OCDclinically signiﬁcant improvement in both his obsessions and
compulsions at 1-month follow-up, which was maintained over
the 12-month treatment course. Moreover, he experienced
enduring improvements in depression, anxiety, and health-
related quality of life after 3 months of HB DBS treatment.
Although we cannot rule out placebo effects, this possibility does
not seem likely, given the patient's long disease duration and
history of multiple treatment failures while showing a sustained
clinical response to HB DBS in this study.
Finally, the HB DBS was well tolerated by the patient, and no
signiﬁcant adverse events occurred during the surgery and
follow-up period.
Based on these results, we tentatively conclude that the HB
could be a new therapeutic target that is distinct from the cortico-
striatal loop circuits traditionally targeted in prior neurosurgical
interventions for severe and refractory cases of OCD. If this
preliminary conclusion turns out to be valid, HB dysfunction
would play an important role in the pathophysiology of OCD, too.
The implication is that OCD pathophysiology could bemulti-focal
or more widespread than previously thought (2), involving not
only abnormal dopaminergic neurotransmission in the striatum
but also abnormal serotonergic function modulated by the HB. To
our knowledge, this case report provides the ﬁrst clinical evidence
suggesting that HB DBS may be a safe and effective interventionFrontiers in Psychiatry | www.frontiersin.org 4for severe and refractory OCD. Our observations seem promising
enough to warrant further research into the role of the HB in
pathophysiology and treatment of OCD.DATA AVAILABILITY STATEMENT
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